Charco Neurotech Ltd is a limited company established in Wellington, New Zealand, focused on developing and commercializing innovative solutions for individuals living with Parkinson’s disease. Founded in 2019, the company operates from its headquarters at Wellington House, Cambridge, CB1 1BH. Charco Neurotech specializes in the research, development, and manufacturing of CUE1 and CUE1+ devices, representing a significant advancement in neurostimulation technology. The company’s core business revolves around creating sophisticated, non-invasive devices designed to modulate neural activity and potentially improve motor function and quality of life for patients with Parkinson’s. Specifically, CUE1 and CUE1+ utilize a proprietary stimulation technique, offering a targeted and potentially more effective approach compared to existing therapies. Charco Neurotech is currently classified as a ‘type’ of ‘manufacture of medical and dental instruments and supplies’ under SIC Code 32500, reflecting its manufacturing capabilities. Furthermore, the company is classified as a ‘research and experimental development on social sciences and humanities’ under SIC Code 72200, highlighting its commitment to scientific exploration and innovation within the field of neurological research. The company is actively expanding its international presence and employs a workforce of skilled individuals.

Charco Neurotech Ltd is a limited company established in Wellington, New Zealand, focused on developing and commercializing innovative solutions for individuals living with Parkinson’s disease. Founded in 2019, the company operates from its headquarters at Wellington House, Cambridge, CB1 1BH. Charco Neurotech specializes in the research, development, and manufacturing of CUE1 and CUE1+ devices, representing a significant advancement in neurostimulation technology. The company’s core business revolves around creating sophisticated, non-invasive devices designed to modulate neural activity and potentially improve motor function and quality of life for patients with Parkinson’s. Specifically, CUE1 and CUE1+ utilize a proprietary stimulation technique, offering a targeted and potentially more effective approach compared to existing therapies. Charco Neurotech is currently classified as a ‘type’ of ‘manufacture of medical and dental instruments and supplies’ under SIC Code 32500, reflecting its manufacturing capabilities. Furthermore, the company is classified as a ‘research and experimental development on social sciences and humanities’ under SIC Code 72200, highlighting its commitment to scientific exploration and innovation within the field of neurological research. The company is actively expanding its international presence and employs a workforce of skilled individuals.